Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations

Fig. 1

a Representative chest computed tomography (CT) from patient 3. Left, baseline CT scan at initial diagnosis. Middle, MPE progression on day 30 after first-line gefitinib administration. Right, CT scan three months after local intervention and continuous gefitinib treatment. Red arrows indicate primary lung lesions. b Hematoxylin & eosin (HE) staining of the pleural effusion smear. Samples from patients 2 and 5 were obtained at initial diagnosis, and the other three samples were obtained at early MPE progression. The red arrow indicates malignant cells. Progressive-free survival (PFS) (c) and overall survival (OS) (d) after first-line gefitinib treatment. #, patients alive at the last follow-up. e Gefitinib concentrations in paired MPE and blood samples from patients 4 and 5. Samples were obtained when the MPE progressed after gefitinib treatment (day 41 for patient 4 and day 39 for patient 5). f Gefitinib concentration versus time plots of one gefitinib-sensitive patient. g Genetic alteration analysis of next-generation sequencing (NGS) results. NA, not available. h Comparison of genetic mutations between paired MPE and tumor tissues of patient 4

Back to article page